Pelitrexol
new

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 202200

CAS#: 446022-33-9

Description: Pelitrexol is a GARFT inhibitor, and is also a water soluble antifolate with anti-proliferative activity. Pelitrexol inhibits activity of glycinamide ribonucleotide formyltransferase (GARFT), the first folate-dependent enzyme of the de novo purine synthesis pathway essential for cell proliferation. Enzyme inhibition reduces the purine nucleotides pool required for DNA replication and RNA transcription. As a result, this agent causes cell cycle arrest in S-phase, and ultimately inhibits tumor cell proliferation.


Price and Availability

Size
Price

1mg
USD 190
Size
Price

2mg
USD 350
Size
Price

5mg
USD 750

Pelitrexol (smaller quantity), purity > 97%, is in stock. The same day shipping out after order is received. Bulk quantity may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 202200
Name: Pelitrexol
CAS#: 446022-33-9
Chemical Formula: C20H25N5O6S
Exact Mass: 463.15255
Molecular Weight: 463.5074
Elemental Analysis: C, 51.83; H, 5.44; N, 15.11; O, 20.71; S, 6.92


Synonym: AG-2037; AG 2037; AG2037; Pelitrexol.

IUPAC/Chemical Name: (S)-2-(5-(2-((S)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl)ethyl)-4-methylthiophene-2-carboxamido)pentanedioic acid

InChi Key: QXOPTIPQEVJERB-JQWIXIFHSA-N

InChi Code: InChI=1S/C20H25N5O6S/c1-9-6-14(18(29)23-12(19(30)31)3-5-15(26)27)32-13(9)4-2-10-7-11-16(22-8-10)24-20(21)25-17(11)28/h6,10,12H,2-5,7-8H2,1H3,(H,23,29)(H,26,27)(H,30,31)(H4,21,22,24,25,28)/t10-,12-/m0/s1

SMILES Code: O=C(O)[C@@H](NC(C1=CC(C)=C(CC[C@H](CN2)CC3=C2N=C(N)NC3=O)S1)=O)CCC(O)=O


Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.03.00


Additional Information

 
 


References

 1. Frost, Gregory I.; Jiang, Ping; Thompson, Curtis B. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions. PCT Int. Appl. (2009), 292 pp. CODEN: PIXXD2 WO 2009128917 A2 20091022 CAN 151:462825 AN 2009:1297488

2. Czarnik, Anthony W. Deuterium-enriched pelitrexol. U.S. Pat. Appl. Publ. (2009), 10pp. CODEN: USXXCO US 2009062316 A1 20090305 CAN 150:314122 AN 2009:270615

3. Habib, Nabil. Treatment of cancer and other diseases. PCT Int. Appl. (2007), 86pp. CODEN: PIXXD2 WO 2007064691 A1 20070607 CAN 147:46112 AN 2007:619578

4. Hu, Shanghui; Kelly, Sean; Lee, Steve; Tao, Junhua; Flahive, Erik. Efficient Chemoenzymatic Synthesis of Pelitrexol via Enzymic Differentiation of a Remote Stereocenter. Organic Letters (2006), 8(8), 1653-1655. CODEN: ORLEF7 ISSN:1523-7060. CAN 144:488917 AN 2006:283608

5. Denis, Louis J.; Compton, Linda D. Method using camptothecin compounds, pyrimidine derivatives, and antitumor agents for treating abnormal cell growth. U.S. Pat. Appl. Publ. (2005), 32 pp. CODEN: USXXCO US 2005272755 A1 20051208 CAN 144:17160 AN 2005:1294044

6. Yaffe, Michael B.; Clapperton, Julie A.; Manke, Isaac A.; Lowery, Drew M.; Ho, Timmy; Haire, Lesley F.; Smerdon, Stephen J. The x-ray crystal structure of BRCA1 tandem BRCT repeat and BACH1 phosphopeptide complex and methods and compositions for antitumor drug design. PCT Int. Appl. (2005), 360 pp. CODEN: PIXXD2 WO 2005115454 A2 20051208 CAN 144:46998 AN 2005:1290072

7. Melton, Roger; Atkinson, Anthony. Use of enzyme carboxypeptidase G for combating toxicity caused by an antifolate compound. PCT Int. Appl. (2005), 54 pp. CODEN: PIXXD2 WO 2005084695 A2 20050915 CAN 143:299139 AN 2005:1004581

8. Lacasse, Eric; McManus, Daniel. Human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy. PCT Int. Appl. (2005), 112 pp. CODEN: PIXXD2 WO 2005042558 A1 20050512 CAN 142:457053 AN 2005:409543

9. Lacasse, Eric; McManus, Daniel; Durkin, Jon P. Sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with a chemotherapeutic agent. PCT Int. Appl. (2005), 285 pp. CODEN: PIXXD2 WO 2005042030 A1 20050512 CAN 142:457052 AN 2005:409357

10. Lee, Margaret S.; Nichols, James M.; Zhang, Yanzhen; Keith, Curtis. Combinations of chlorpromazine compounds and antiproliferative drugs for the treatment of neoplasms. PCT Int. Appl. (2005), 65 pp. CODEN: PIXXD2 WO 2005027842 A2 20050331 CAN 142:349042 AN 2005:283298

11. Dovalsantos, Elena Zapata; Flahive, Erik Jon; Halden, Brian John; Mitchell, Mark Bryan; Notz, Wolfgang Reinhard Ludwig; Tian, Qingping; O'Neil-Sla Wecki, Stacy Ann. Convergant synthesis of a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor containing a methyl substituted thiophene core and a tetrahydropyrido[2,3-d]pyrimidine ring system and intermediates therefor. PCT Int. Appl. (2004), 36 pp. CODEN: PIXXD2 WO 2004113337 A1 20041229 CAN 142:94129 AN 2004:1154710

12. Martinez, Carlos Alberto; Notz, Wolfgang Reinhard Ludwig. Convergent asymmetric synthesis route to produce a key intermediate towards the synthesis of a glycinamide ribonucleotide formyl transferase (GARFT) inhibitor. PCT Int. Appl. (2004), 38 pp. CODEN: PIXXD2 WO 2004113328 A1 20041229 CAN 142:74839 AN 2004:1154701

13. Fotoohi, Kambiz; Jansen, Gerrit; Assaraf, Yehuda G.; Rothem, Lilah; Stark, Michal; Kathmann, Ietje; Gregorczyk, Jacek; Peters, Godefridus J.; Albertioni, Freidoun. Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: Implications for efficacy of methotrexate therapy. Blood (2004), 104(13), 4194-4201. CODEN: BLOOAW ISSN:0006-4971. CAN 142:169330 AN 2004:1121011

14. Carson, Dennis A.; Leoni, Lorenzo M. Compositions and methods for the detection, prognosis, and treatment of methylthioadenosine phosphorylase deficient cancers using antibodies. PCT Int. Appl. (2004), 82 pp. CODEN: PIXXD2 WO 2004074325 A2 20040902 CAN 141:239297 AN 2004:718572

15. Bronder, Julie L.; Moran, Richard G. A Defect in the p53 Response Pathway Induced by de Novo Purine Synthesis Inhibition. Journal of Biological Chemistry (2003), 278(49), 48861-48871. CODEN: JBCHA3 ISSN:0021-9258. CAN 140:35493 AN 2003:935783

16. Bloom, Laura Anne; Boritzki, Theordore James; Kung, Pei-Pei; Ogden, Richard Charles; Skalitzky, Donald James; Zehnder, Luke Raymond; Kuhn, Leslie Ann; Meng, Jerry Jialun. Combination therapies for treating methylthioadenosine phosphorylase deficient cells. PCT Int. Appl. (2003), 189 pp. CODEN: PIXXD2 WO 2003074083 A1 20030912 CAN 139:246208 AN 2003:719328